EUROPE BOTULINUM TOXIN MARKET FORECAST 2023-2032

The Europe botulinum toxin market growth analysis entails the evaluation of Spain, France, Italy, Poland, Nordic Countries, Germany, the United Kingdom, and Rest of Europe. The United Kingdom boasts a well-established healthcare system that is helping improve the health of its citizens. The country has made significant progress in healthcare development, providing complete public services free at the point of utilization, resulting in lower healthcare expenditure for individuals. In response to this growing trend, leading players in the botulinum toxin market focus on ongoing innovation and upgrading their product portfolio for better aesthetics and enhanced patient therapeutic outcomes.

Cosmetic surgery has seen a surge in demand in the United Kingdom as people seek to improve their physical appearance. With their vast experience in this field and the use of the latest technologies, German specialists have provided significant results, fueling the demand for cosmetic surgeries across the country. Modern techniques and methods of cosmetic surgery allow for high accuracy and help patients change their appearance while maintaining a natural look without risking their health.

Germany is expected to witness significant growth in botulinum toxin procedures, driven by increasing public awareness, an aging population, and a growing inclination toward cosmetic appearances. According to the International Society of Aesthetic Plastic Surgery (ISAPS) 2018 Statistics, non-surgical cosmetic procedures in Germany increased from about 536,150 in 2018 to 605,942 total non-surgical procedures in 2021.

The Europe botulinum toxin market segmentation assessment includes end-user, type, application, and user demographic. Market by type includes type A botulinum toxin and type B botulinum toxin.

Botulinum toxin type B, an alternative neurotoxin derived from Clostridium botulinum, is widely accepted for medical treatments. Type A and type B differ in their mechanism of action. Type A and type B attach to the receptor sites on motor neuron terminals, inhibiting acetylcholine release. 

Studies have evaluated the safety and efficacy of botulinum toxin type B in treating Hidradenitis Suppurativa and have found that it can improve the overall symptoms of the disease. Further research conducted at Boston’s Children’s Hospital has shown that introducing key amino acids through genetic engineering on the lipid-binding loop in botulinum toxin type B can make it more effective, longer-lasting, and exhibit fewer side effects. In August 2019, Myobloc (rimabotulinumtoxinB) received US FDA approval for treating chronic sialorrhea in adults, which is expected to contribute to the market’s growth. These developments highlight the potential for botulinum toxin type B in medical treatments and are expected to drive market growth in the coming years.

Leading companies operating in the Europe botulinum toxin market include Ipsen, Merz Pharma, etc.

Ipsen is a global specialty biopharmaceutical company that focuses on developing and commercializing novel medicines for cancer, neurological diseases, and rare diseases, including specialty pharmaceutical products. In addition, the company offers products to treat various conditions, such as gastrointestinal disorders, neurodegenerative pathologies, and rheumatic diseases. 

Ipsen distributes its drugs through a network of distributors and directly to hospitals in select countries. The company operates research and development facilities in Paris-Saclay, France; Oxford, the United Kingdom; and Cambridge, the United States, with headquarters in Paris, France.

One of Ipsen’s pharmaceutical products is Dysport (abobotulinumtoxin A), an acetylcholine release inhibitor and neuromuscular blocking agent. The medication is widely used in the cosmetic industry and has been approved for various medical indications, such as the treatment of muscle spasms and cervical dystonia.